Short answer
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an 8-K current report with the SEC on July 14, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item 2.03 (Creation of a Direct Financial Obligation). $75.0M Tranche A funded July 10, 2026, refinancing prior debt and leaving approximately $20.0M for corporate and working capital.
KESTRA MEDICAL TECHNOLOGIES, LTD. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $75.0M Tranche A funded July 10, 2026, refinancing prior debt and leaving approximately $20.0M for corporate and working capital
- Total facility up to $200.0M through 2031, including $75.0M funded and $125.0M contingent or acquisition capacity
- Variable interest rate: 5.50% plus three-month SOFR, with a 3.25% SOFR floor, increasing exposure to rates
- 48 months interest-only, followed by four equal quarterly amortization payments beginning fiscal Q2 2030
- Substantially all assets, including intellectual property, secure the debt; $20.0M minimum liquidity covenant constrains cash deployment
Item 1.02 · Termination of a Material Definitive Agreement
- Prior Loan Agreement with Perceptive Credit Holdings IV terminated upon July 10, 2026 Loan Agreement
- Borrower’s payment and other obligations fully paid and discharged
- Prior Lender’s security interests in company assets and property released
- Refinancing removed the prior lender’s claims against company collateral
Item 2.02 · Results of Operations and Financial Condition
- Fiscal quarter ended April 30, 2026 results announced on July 14, 2026
- Exhibit 99.1 contains the detailed financial results and management commentary
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 links to Item 1.01, indicating a material financial obligation arose under the related agreement
- Investors should review Item 1.01 for the obligation’s amount, payment terms, maturity, and business purpose
Item EX-99.1 · Exhibit EX-99.1
- FY26 revenue $95.1M, up 59%, with ASSURE prescriptions up 57% to 20,720
- Gross margin expanded to 51.4% from 40.5%, signaling improving unit economics and reimbursement mix
- FY26 GAAP net loss widened to $131.6M, while adjusted EBITDA loss increased to $87.0M
- Cash, cash equivalents, and investments totaled $262.2M, but operating cash use reached $81.7M
- FY27 revenue guidance of $137M implies 44% growth, raising execution expectations for commercial expansion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other KESTRA MEDICAL TECHNOLOGIES, LTD. 8-K filings
Get the next KMTS 8-K as it lands
Follow KMTS for push alerts, or ask the research agent what this filing means.